TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00436007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK 257049
Description: GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK 257049
Description: GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™ HepB/Hib
Description: GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™ HepB/Hib
Description: GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™ HepB/Hib
Description: GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rouvax™
Description: Aventis Pasteur's attenuated measles vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rouvax™
Description: Aventis Pasteur's attenuated measles vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rouvax™
Description: Aventis Pasteur's attenuated measles vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril™
Description: Aventis Pasteur's attenuated yellow fever vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril™
Description: Aventis Pasteur's attenuated yellow fever vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril™
Description: Aventis Pasteur's attenuated yellow fever vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: GSK Biologicals' oral polio virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: GSK Biologicals' oral polio virus vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin™
Description: GSK Biologicals' oral polio virus vaccine
Study: NCT01106963

Intervention type: PROCEDURE
Intervention: Tibial intramedullary nailing
Description: Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
Study: NCT04622709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide (loop diuretic) Tablets
Description: Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
Study: NCT04553575

Intervention type: BIOLOGICAL
Intervention: serology
Description: biological blood samples withdrawn at 6, 12 and 24 months
Study: NCT00532337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-5334
Description: Placebo - 24/mos.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 100mg QD /24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 50mg BID /24 mos.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 300mg QD /24 mos.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONO-5334
Description: Alendronate 70mg once weekly / 24 mos
Study: NCT02684552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: Training on treadmill with Non invasive ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Training on treadmill with oxygen
Study: NCT04173936

Intervention type: BEHAVIORAL
Intervention: tai chi
Description: 12-week community-based tai chi program
Study: NCT00537147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN/DEN4delta30 vaccine
Description: Live attenuated WN/DEN4delta30 vaccine (one of two doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN/DEN4delta30 vaccine
Description: Live attenuated WN/DEN4delta30 vaccine (one of two doses)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for WN/DEN4delta30 vaccine
Study: NCT03712722

Intervention type: OTHER
Intervention: Faecal microbiota transplantation (FMT)
Description: FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces
Study: NCT03056248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
Study: NCT01941095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
Study: NCT02852564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethacrynic Acid
Description: One oral dose at 50 mg prior to bladder tumor removal surgery
Study: NCT03536338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Stimulation
Description: transcutaneous electrical stimulation of the lumbar spinal cord during rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sit-to-stand Training
Description: Rehabilitation of standing from a chair using the Keiser Rack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-to-stand Training
Description: Rehabilitation of standing from a chair using the Keiser Rack
Study: NCT03080649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: excavated with rotary bur
Description: One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
Study: NCT02080923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview
Description: The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
Study: NCT03991156

Intervention type: DEVICE
Intervention: Audio-Visual Assisted Therapeutic Ambience in Radiotherapy
Description: Audio Visual System

Intervention type: OTHER
Intervention: Quality of Life Survey, PedsQL3.0
Description: Quality of life survey using the PedsQL 3.0 Cancer Module

Intervention type: OTHER
Intervention: Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)
Description: Yale Preoperative Anxiety Scale Short Form (mYPAS-SF).\[24\] is a survey to measure anxiety
Study: NCT02834000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCO rapid™ CNAP monitoring
Description: LiDCO rapid™ CNAP monitoring allows through analysis of the arterial blood pressure trace to acquire information about CO, HR variability, SVR, SV and BIS during general anaesthesia.
Study: NCT00154180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated equine estrogens 0.45 mg/day
Description: Pill, 1 pill taken daily each month for the study duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal estradiol, 50 mcg/day
Description: Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone, 200 mg/day x 12 d/month
Description: capsule, 1 capsule taken daily for the first 12 days of each month for the study duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CEE , progesterone, estradiol patch or placebo for each
Description: CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEE, progesterone, transdermal patch or the placebo
Description: CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CEE, progesterone, transdermal patch or the placebo
Description: CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
Study: NCT02295878

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment capsule containing seaweed extract (treatment)
Description: 400mg capsule containing seaweed extract (treatment)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01775319

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biofortified wheat
Description: Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified wheat
Description: Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02361047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Coaching Program
Description: Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
Study: NCT01434121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04277533

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)
Description: GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)
Description: GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.
Study: NCT01096927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin and Clavulanic Acid
Description: 7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
Study: NCT01634906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temporary discontinuation of statin therapy
Description: All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
Study: NCT03085173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRt/19-28z/4-1BBL CAR T cells
Description: Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10\^5, 3 x 10\^5, 1 x 10\^6, and 3 x 10\^6 CAR T cells/kg.
Study: NCT01176448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated laser
Description: Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
Study: NCT01552096

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peritonsillar infiltration
Description: 1.5 ml around each tonsil, 3 minutes before surgical incision as per group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peritonsillar infiltration
Description: 1.5 ml around each tonsil, 3 minutes before surgical incision as per group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peritonsillar infiltration
Description: 1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
Study: NCT01046123

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
Description: Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
Study: NCT03676803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed spices
Description: All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano, 1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of 5.0g spice mixture. They are identical to herbs and spices sold in grocery stores for human consumption.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule containing 5 g of maltodextrin
Description: placebo capsule containing 5 g of maltodextrin
Study: NCT02910609

Intervention type: DEVICE
Intervention: Echocardiography
Description: Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.

Intervention type: DEVICE
Intervention: Echocardiography
Description: Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
Study: NCT00655577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised, mainly home-based balance, strength and jumping exercises

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise
Description: Supervised, mainly home-based balance, strength and jumping exercises
Study: NCT00102908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: Zoledronate infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronate placebo
Description: Zoledronate placebo infusion
Study: NCT02045121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indwelling Pleural Catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Talc Pleurodesis
Study: NCT02531984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Study: NCT04419337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus Pioglitazone plus an SGLT2 inhibitor
Description: Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin plus Pioglitazone plus an SGLT2 inhibitor
Description: Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.
Study: NCT03728842

Intervention type: OTHER
Intervention: Blood collection for laboratory studies
Description: Peripheral whole blood will be collected

Intervention type: OTHER
Intervention: Data collection from medical record
Description: Clinical data such as demographics and cancer characteristics, history and treatment will be collected
Study: NCT02319928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Study: NCT01297049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Description: All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
Study: NCT00520741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide
Description: 50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
Study: NCT03344510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinetic Anesthesia Device
Description: A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinetic Anesthesia Device
Description: A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: One injection will be administered without the kinetic anesthesia device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: One injection will be administered without the kinetic anesthesia device.
Study: NCT01328275

Intervention type: DRUG
Intervention: standard regimens according to the Thai Ministry of Public Health national guidelines
Description: Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
Study: NCT02554864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Local anesthetic
Study: NCT02625948

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study: NCT01060670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integra® Dermal Regeneration Template
Description: Application of Integra® Dermal Regeneration Template in diabetic foot ulcer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Wound Therapy
Description: Conventional Wound Therapy